Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan

doi:10.12092/j.issn.1009-2501.2019.06.016

Abstract

Abstract:

AIM: To investigate the efficacy of agomelatine in the treatment of depressive disorder and its effect on brain-derived neurotrophic factor (BDNF). METHODS: A total of 90 patients with depression admitted to our hospital from March 20 to December 2018 were randomly divided into observation group (45 cases) and control group (45 cases). The observation group was treated with agomelatine, the control group was treated with venlafaxine, and the clinical efficacy, BDNF level and adverse reactions were observed after 4 weeks. RESULTS:The effective rate of the observation group was 73.33% and the effective rate of the control group was 62.22%. There was no significant difference in the effective rate between the two groups (P>0.05). The HAMD and HAMA scores of the two groups were significantly lower than those before treatment (P<0.05), the HAMD scores of the observation group were significantly lower than those of the control group (P<0.05), and the HAMA scores of the observation group were significantly higher than the control group (P<0.05). Pearson correlation analysis showed that BDNF level was negatively correlated with HAMD and HAMA scores (P<0.05), and positively correlated with HAMD reduction rate (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05).CONCLUSION:Agomelatine can effectively improve the symptoms of depression and anxiety, significantly reduce the level of BDNF and has better safety.

Key words: agomelatine, venlafaxine, depression, brain-derived neurotrophic factor, anxiety

CLC Number:

R749

ZHOU Yancan. Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 699-703.

References

［1］林芳波,侯德仁,唐秋萍. 抑郁症的药物治疗进展及艾氯胺酮的应用前景［J］. 南方医科大学学报,2017,37(4):567-569.
［2］顾翠,可秦,张平,等. 米氮平联合西酞普兰治疗抑郁症患者睡眠障碍的临床观察［J］. 中国药房,2017,28(5):670-673.
［3］熊丽丽,姬劲峰.帕罗西汀与文拉法辛治疗首发抑郁症的效果比较［J］. 实用医药杂志,2017,34(2):142-143.
［4］曹曙光. 文拉法辛和米氮平治疗难治性抑郁症的效果比较［J］. 中国医药指南, 2017, 15(31):136-137.
［5］许峰,王建民,焦宗久,等. 不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效分析［J］. 国际精神病学杂志,2017,44(1):82-84+101.
［6］牛娟,陈晓芹,周田田,等. 阿戈美拉汀治疗首发老年抑郁症的疗效研究［J］.国际精神病学杂志,2018,45(1):65-67.
［7］郭俊慧,王高华,朱志先,等. 脑源性神经营养因子对重症抑郁及其认知功能障碍的影响［J］. 神经损伤与功能重建,2017,12(6):526-528.
［8］卢瑾,李凌江,许秀峰. 中国抑郁障碍防治指南（第二版）解读：评估与诊断［J］. 中华精神科杂志,2017,50(3):169-171.
［9］宁征远,谢姗姗,李健,等. 阿戈美拉汀联合坦度螺酮对老年抑郁症患者血清NE、5-HT水平的影响［J］. 东南国防医药,2017,19(3):251-253.
［10］杨晓钟,马雯霞. 5-HT再摄取抑制剂对抑郁症患者睡眠质量和疗效的影响［J］. 河北医学,2018,24(10):1630-1634.
［11］周严灿,平晶,单建敏. 乌灵胶囊联合阿戈美拉汀对女性抑郁伴睡眠障碍患者的疗效及对神经递质和内分泌激素的影响［J］. 中国临床药理学与治疗学,2018,23(12):1415-1419.
［12］Gupta K, Gupta R, Bhatia MS, et al. Effect of agomelatine and fluoxetine on hamd score, serum brain-derived neurotrophic factor, and tumor necrosis factor-α level in patients with major depressive disorder with severe depression［J］. J Clin Pharmacol, 2017,57(12):1519-1526.
［13］Kennedy SH, Heun R, Avedisova A,et al. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder［J］. J Affect Disord,2018,238:122-128.
［14］孙毅,卓越,吕治宇,等.不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效观察［J］. 临床合理用药杂志,2018,11(11): 39-40.
［15］杨志,迟强,栾中山.阿戈美拉汀与文拉法辛治疗抑郁症的临床对照研究［J］.神经损伤与功能重建,2015,10(4):356-357.
［16］李正华. 文拉法辛缓释片治疗广泛性焦虑症对照研究［J］. 精神医学杂志,2012,25(3):195-196.
［17］Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis［J］. Psychopharmacology(Berl),2008,196(4):511-520.
［18］胡晓蕊,沈宗霖,许秀峰. 脑源性神经营养因子与抑郁症关系的研究［J］. 临床精神医学杂志,2017,27(2):137-139.
［19］杨和增,单菲,李敏智.围绝经期抑郁症患者文拉法辛治疗前后脑源性神经营养因子的变化［J］. 实用医学杂志,2018,34(3):457-459.
［20］关书,熊伟,高云.脑源性神经营养因子与抑郁症［J］. 中国药理学通报,2018,34(2):153-156.
［21］公维谦,陈玉社,赵燕,等. 抑郁症合并2型糖尿病患者血浆BDNF水平与抑郁焦虑症状、TG的相关性［J］. 国际精神病学杂志,2017,44(3):398-400+403.
［22］汪卫华,刘丽,李光耀,等. 抑郁症患者血清瘦素和脑源性神经营养因子与疗效的相关性［J］. 临床精神医学杂志,2015,25(5):332-334.

[1]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[2]	WANG Xin, WU Guodong, AN Ming, LI Gang, LIU Yang. Advances in venlafaxine-related PK-PD relationship and influencing factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 788-795.
[3]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[4]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[5]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[6]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[7]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[8]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[9]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[10]	DING Lulu, GUO Jianyou. Neurobiological factors of trait anxiety and its influences on individual cognitive performance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 101-106.
[11]	WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.
[12]	LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909.
[13]	CHEN Lianzhou, LI Songhua, PU Ben. Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 446-450.
[14]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.
[15]	WANG Rouxin, FANG Zekang, YAO Siqi, XUE Yingying, ZHAO Yeying, YE Yilu. Effects of nicotinamide ribose on adolescent depression rats after neonatal maternal deprivation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1015-1021.